

## Instructions for Authors 2022

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

AR provides for the prompt print and online publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work (without supplementary data), and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work or before the Acknowledgements); (b) *Abstract* not exceeding 250 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors’ Contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures (graphs and photographs).** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Figures should be prepared at a width of 8 or 17cm with eligible symbols, lettering and numbers. The number of each figure must be indicated. Pages that include color figures are subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Each table may have 2-10 vertical columns. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dagleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticanres.12924 (PMIDs and DOIs only if

applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at: [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index2.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html) [Last accessed on April 3, 2018]. (The web address should link directly to the cited information and not to a generic webpage).

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC -IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email ([iar@iar-anticancer.org](mailto:iar@iar-anticancer.org)) within 24 hours.

### **Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 5 days from submission, the author should contact the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for peer-review (single-blind) in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
  5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
  6. Authors should pay attention to the following points when writing an article for AR:
    - The Instructions to Authors must be followed in every detail.
    - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
    - The presentation of results should be simple and straightforward in style. Results and Discussion should not be combined into one section.
    - Results given in figures should not be repeated in tables.
    - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
    - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
    - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
    - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
    - References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
    - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
  7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
  8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably in red. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
  9. All Authors will be asked to supply author contribution and conflict of interest forms.
  10. Articles submitted to AR may be rejected without review if:
    - they do not fall within the journal's policy.
    - they do not follow the instructions for authors.
    - language is unclear.
    - results are not sufficient to support a final conclusion.
    - results are not objectively based on valid experiments.
    - they repeat results already published by the same or other authors before the submission to AR.
    - plagiarism is detected by plagiarism screening services.
 (Rejection rate (2021): 69%).
  11. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
  12. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
  13. Authors who wish to organize and edit a special issue on a particular topic should contact the Managing Editor.
  14. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2022** – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers. M. KACZOROWSKI, J. MATYSIAK, P. KIELB, B. MALKIEWICZ, A. HALON ( <i>Wroclaw, Poland</i> ).....	493
Dipeptidyl Peptidase-4 from Cancer-associated Fibroblasts Stimulates the Proliferation of Scirrhus-type Gastric Cancer Cells. S. KUSHIYAMA, M. YASHIRO, Y. YAMAMOTO, T. SERA, A. SUGIMOTO, S. NISHIMURA, S. TOGANO, K. KURODA, T. OKUNO, Y. MIKI, M. OHIRA ( <i>Osaka, Japan</i> ).....	501
Epstein-Barr Virus-induced Gene 3 as a Novel Biomarker in Metastatic Melanoma With Infiltrating CD8 <sup>+</sup> T Cells: A Study Based on The Cancer Genome Atlas (TCGA). S. YONEKURA ( <i>Villejuif, France</i> ) .....	511
14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion via Matrix Metalloproteinase-1 Regulation in Human Gastric Cancer. J.Y. JUNG, S.A. KOH, K.H. LEE, J.R. KIM ( <i>Daegu, Republic of Korea</i> ).....	519
<i>Helicobacter pylori</i> Targets in AGS Human Gastric Adenocarcinoma: <i>In Situ</i> Proteomic Profiling and Systematic Analysis. J.-S. YANG, C.-Y. KANG, C.-H. SU, C.-J. CHEN, Y.-J. CHIU, Y.-M. HSU ( <i>Taichung; Taipei, Taiwan, ROC</i> ).....	531
Effect of Alpha-tocopheryl Succinate on the Cytotoxicity of Anticancer Drugs Towards Leukemia Lymphocytes. D. IVANOVA, Z. ZHELEV, G. ZLATEVA, D. LAZAROVA, Z. YANEVA, R. PANOVSKA, I. AOKI, R. BAKALOVA ( <i>Stara Zagora; Sofia, Bulgaria; Chiba, Japan</i> ).....	547
Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells. S.H. MOON, N.-S. PARK, M.H. NOH, Y.S. KIM, S.H. CHEONG, D.Y. HUR ( <i>Busan, Republic of Korea</i> ) .....	555
Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen. G.B. HENRIQUES PALMA, M. KAUR ( <i>Johannesburg, South Africa</i> ).....	565
Nerve Growth Factor in Breast Cancer Cells Promotes Axonal Growth and Expression of Calcitonin Gene-related Peptide in a Rat Model of Spinal Metastasis. A. MAZAKI, K. YAMAUCHI, S. ORITA, K. INAGE, M. SUZUKI, K. FUJIMOTO, Y. SHIGA, K. ABE, M. INOUE, M. NORIMOTO, T. UMIMURA, S. OHTORI ( <i>Chiba, Japan</i> ) .....	581
Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stressmediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells. J. HWANG, A. PARK, C. KIM, D. YU, H. BYUN, M. KU, J. YANG, T.I. KIM, K.-S. JEONG, K.Y. KIM, H. LEE, S.J. SHIN ( <i>Seoul; Daejeon, Republic of Korea</i> ) .....	589
Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma. B. MWESIGE, M.R. LEE, Y.-S. LEE, N.Y. HAN, J.E. IM, J.-K. KIM, S.I. CHOI, E.K. HONG, A.-R. JEON, S.-J. PARK, S.M. WOO, Y.-H. KIM ( <i>Goyang; Seoul, Republic of Korea</i> ).....	599
Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet. K.-I. INOUE, H. YAMAGISHI, T. JOJIMA, T. INOUE, S. TOYODA ( <i>Tochigi, Japan</i> ).....	609

Excellent Response to MEK Inhibition in an <i>AGK-BRAF</i> Gene Fusion Driven Carcinoma: Case Report and Literature Review. A. DOMEN, C. VAN PAESSCHEN, K. ZWAENEPOEL, S. LAMBIN, P. PAUWELS, M. RASSCHAERT, E. SEGELOV, M. PEETERS, H. PRENEN ( <i>Antwerp; Edegem, Belgium; Clayton, VIC, Australia</i> ) .....	373
A Case of Mesenteric Desmoid Tumor Causing Bowel Obstruction After Laparoscopic Surgery. K. ARIMA, Y. KOMOHARA, T. UCHIHARA, K. YAMASHITA, S. UEMURA, N. HANADA, H. BABA ( <i>Kagoshima; Kumamoto, Japan</i> ) .....	381
<i>Experimental Studies</i>	
A Single Nucleotide Polymorphism (SNP) in the <i>SLC22A3</i> Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. J. LI, A.K. PERSAUD, J.A. JOHNSON, D.W. SBOROV, M.A. PHELPS, C.C. HOFMEISTER, M.J. POI ( <i>Columbus, OH; Salt Lake City; Atlanta, GA, USA</i> ) .....	385
Moderate Intensity Endurance and Resistance Exercise Attenuates Cachexia in Tumor-bearing Mice. N.R. WOOD, J. GARRITSON, A. MATHIAS, J.M. HAUGHIAN, R. HAYWARD ( <i>Greeley, CO, USA</i> ) .....	397
High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter. M. IKEDA, Y. KOH, J. OYANAGI, S. TERAOKA, M. ISHIGE, Y. FUJIMURA, K. TAKEDA, N. TOKUDOME, Y. OZAWA, H. UEDA, N. YAMAMOTO ( <i>Wakayama; Tokyo, Japan</i> ) .....	407
Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software. H. MIYATA, Y. AKIYAMA, A. IIZUKA, R. KONDOU, C. MAEDA, A. KANEMATSU, K. WATANABE, T. ASHIZAWA, T. NAGASHIMA, K. URAKAMI, K. OHSHIMA, T. KAWATA, K. MURAMATSU, A. SHIOMI, M. TERASHIMA, T. SUGINO, A. NOTSU, K. MORI, K. YAMAGUCHI ( <i>Shizuoka; Tokyo, Japan</i> ) .....	419
MUC1 and CD147 Are Promising Markers for the Detection of Circulating Tumor Cells in Small Cell Lung Cancer. B. SAVARESE-BRENNER, M. HEUGL, B. RATH, C. SCHWEIZER, E. OBERMAYR, S. STICKLER, G. HAMILTON ( <i>Vienna, Austria</i> ) .....	429
A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring <i>EGFR</i> L747P Mutation With Clinical Response to Multi-targeted Epigenetic and <i>EGFR</i> Inhibition. S.S. MESSEHA, M.A. NEZAMI, S. HAGER, K.F.A. SOLIMAN ( <i>Tallahassee, FL; Newport Beach; Fresno, CA, USA</i> ) .....	441
Clinicopathological Analysis of Non-B Non-C Hepatocellular Carcinoma Focusing on Cellular Proliferation. S. MIZUOCHI, J. AKIBA, R. KONDO, H. KUSANO, T. SHIOGA, K. KONDO, K. TSUTSUI, M. NAKAYAMA, S. OGASAWARA, Y. NAITO, O. NAKASHIMA, H. YANO ( <i>Kurume; Kitakyushu, Japan</i> ) .....	449
CD15+ Bone Marrow-derived Cells Are Regulators of Immune Response in ARG1-producing Colorectal Cancer Cells. K. MIYOSHI, E. SATO, K. KATSUMATA, G. FUKUSHIMA, R. UDO, E. NISHIMURA, T. TAGO, K. KASAHARA, J. MAZAKI, M. ENOMOTO, T. ISHIZAKI, Y. NAGAKAWA, A. TSUCHIDA ( <i>Tokyo, Japan</i> ) .....	459
Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells. C. KIM, S. LEE, D. KIM, D.S. LEE, E. LEE, C. YOO, K.-P. KIM ( <i>Seoul, Republic of Korea</i> ) .....	471
Eupatilin Suppresses Pancreatic Cancer Cells <i>via</i> Glucose Uptake Inhibition, AMPK Activation, and Cell Cycle Arrest. T.H. PARK, H.S. KIM ( <i>Seoul, Republic of Korea</i> ) .....	483

Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. A. MINATO, H. NOGUCHI, R. KIMURO, H. MIRII, N. YUJIRO, Y. HASEGAWA, I. TOMISAKI, K. HARADA, N. FUJIMOTO ( <i>Kitakyushu; Kagoshima, Japan</i> ) .....	263
Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma. Y. YASUDA, T. NAGANO, N. JIMBO, T. KIRIU, R. SURAYA, D. HAZAMA, M. YAMAMOTO, Y. MANIWA, Y. NISHIMURA, K. KOBAYASHI ( <i>Kobe, Japan</i> ).....	271
Clinical Significance of Serglycin Expression in Human Breast Cancer Patients. K. HOSOYA, K. NOSAKA, T. SAKABE, M. WAKAHARA, Y. OSHIMA, Y. SUZUKI, H. NAKAMURA, Y. UMEKITA ( <i>Yonago, Japan</i> ) .....	279
Predictive Factors of Late Cervical Lymph Node Metastasis Using Intraoral Sonography in Patients With Tongue Cancer. M. KONISHI, M. FUJITA, K. SHIMABUKURO, P. WONGRATWANICH, N. KAKIMOTO ( <i>Hiroshima, Japan</i> ).....	287
Reirradiation Using <sup>198</sup> Au Grain Brachytherapy for Recurrent Oral Cancer Cases Previously Treated by Definitive Radiotherapy. M. KONISHI, Y. TAKEUCHI, K. KUBO, N. IMANO, I. NISHIBUCHI, Y. MURAKAMI, K. SHIMABUKURO, P. WONGRATWANICH, N. KAKIMOTO, Y. NAGATA ( <i>Hiroshima, Japan</i> ).....	293
Preoperative Masseter Muscle Sarcopenia Predicts Mortality in Patients With Oesophageal Cancer. T. KAMADA, H. OHDAIRA, E. ITO, Y. FUSE, J. TAKAHASHI, K. NAKASHIMA, Y. NAKASEKO, M. YOSHIDA, K. ETO, Y. SUZUKI ( <i>Tochigi; Tokyo, Japan</i> ) .....	301
The Effect of Smoking on Progression from Ductal Carcinoma <i>In Situ</i> to Invasive Ductal Breast Carcinoma: A Retrospective Study. K. TAKADA, S. KASHIWAGI, Y. ASANO, W. GOTO, T. MORISAKI, M. SHIBUTANI, H. TANAKA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ) .....	311
Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis. K. HAYASHI, O. SUZUKI, H. SHIOMI, M. NAKAI, K. FUJIWARA, E. NAKANISHI, S. TATEKAWA, T. HIRATA, K. TAMARI, H. HIRATA, S. FUNAKI, Y. SEO, Y. TAKEDA, F. ISOHASHI, Y. SHINTANI, K. OGAWA ( <i>Suita; Osaka, Japan</i> ) .....	321
Multiparametric MRI-guided Hypofractionated Intensity-modulated Radiation Therapy With Simultaneous Integrated Boost for Glioblastoma. Y. HAMA, E. TATE ( <i>Tokyo, Japan</i> ) .....	329
Association of <i>MGMT</i> Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type <i>IDH</i> Glioblastoma. M. KIM, J. YOO, J.H. CHANG, S.H. KIM ( <i>Daegu; Seoul, Republic of Korea</i> ).....	335
A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain. K. UCHIYAMA, Y. SAITO, T. SAKAMOTO, Y. TAKEKUMA, Y. KOMATSU, M. SUGAWARA ( <i>Sapporo, Japan</i> ).....	343
Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer. J. LEE, J.M. KIM, Y.H. LEE, G.O. CHONG, D.G. HONG ( <i>Daegu, Republic of Korea</i> ).....	349
Prognostic Value of Copine 1 in Patients With Renal Cell Carcinoma. I.M. TALAAT, E. ABU-GHARBIEH, A. HUSSEIN, M. HACHIM, I. SOBHY, M. ELADL, W. EL-HUNEIDI ( <i>Sharjah; Dubai, United Arab Emirates; Alexandria, Egypt</i> ) .....	355
The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study. E.J. LEE, S.J. PARK, J. LEE, J. MUN, H. PAIK, A. SEOL, J. KIM, G.W. YIM, S.-H. SHIM, H.S. KIM, S.-J. CHANG ( <i>Seoul; Goyang; Suwon, Republic of Korea</i> ).....	363

Prognostic Impact of Upfront Surgery for Locally Advanced Upper Rectal Adenocarcinoma. O. MULLER, R. SINDAYIGAYA, S. CHOMICKI, E. KARAM, N. TABCHOURI, N. MICHOT, D. MOUSSATA, T. LECOMTE, S. CHAPET, G. CALAIS, U. GIGER-PABST, E. SALAME, M. OUAISSI ( <i>Chambray Les Tours; Tours, France; Düsseldorf, Germany</i> ).....	155
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. R. IACOVELLI, C. CICCARESE, O. CAFFO, U. DE GIORGI, U. BASSO, M. TUCCI, C. MOSILLO, M. MARUZZO, F. MAINES, C. CASADEI, M. MILELLA, G. TORTORA ( <i>Rome; Trento; Meldola; Padua; Turin; Terni; Verona, Italy</i> ) .....	165
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan. N. SHIMOZATO, T. NAMISAKI, A. OKANO, M. OHANA, D. KINOSHITA, T. KAWASAKI, Y. AIHARA, T. NAKATANI, H. KINOSHITA, T. ANN, K. SAITO, M. YOSHIDA, H. YOSHIJI ( <i>Kashihara; Tenri; Ikoma; Nara; Sakai; Sango, Japan</i> ) .....	173
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma. S. QUESADA, E. SAMALIN, S. THEZENAS, L. KHELLAF, A. MOURREGOT, F. PORTALES, T. MAZARD, M. YCHOU, A. ADENIS ( <i>Montpellier, France</i> ) .....	185
ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer. T. YOSHIDA, T. NISHINO, M. GOTO, S. INOUE, S. FUJIWARA, H. TAKIZAWA, A. TANGOKU, H. UEHARA, Y. BANDO ( <i>Tokushima, Japan</i> ) .....	195
Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation. R. TOYA, T. WATAKABE, D. MURAKAMI, T. MATSUYAMA, T. SAITO, Y. FUKUGAWA, K. NISHIMOTO, Y. ORITA, N. OYA ( <i>Kumamoto, Japan</i> ).....	205
The Role of Indocyanine Green in Laparoscopic Low Anterior Resections for Rectal Cancer Previously Treated With Chemo-radiotherapy: A Single-center Retrospective Analysis. A. BRESCIA, E.M. MUTTILLO, I. ANGELICONE, I. MADAFFARI, F. MAGGI, I. SPERDUTI, M. GASPARRINI, M. FALCHETTO OSTI ( <i>Rome, Italy</i> ) .....	211
Pancreatectomy With Artery <i>En-bloc</i> Resection for Pancreatic Neck/Body Cancer: A Single-arm Pilot Study. K.-I. OKADA, M. KAWAI, S. HIRONO, S. HAYAMI, M. MIYAZAWA, Y. KITAHATA, M. UENO, R. KOBAYASHI, A. MIYAMOTO, Y. WADA, S. ASAMURA, H. YAMAUE ( <i>Wakayama, Japan</i> ) .....	217
Impact of Tumor Growth Speed of Primary Lesions on the Clinical Outcomes of Appendicular Skeletal Metastases. Y. ASANO, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, S. MIWA, K. IGARASHI, H. YONEZAWA, Y. ARAKI, S. MORINAGA, S. SAITO, T. NOJIMA, H. TSUCHIYA ( <i>Kanazawa, Japan</i> ).....	229
Tumor Location on the Vertical Section of the Anterior Wall Is Related to Favorable Prognosis and Low Incidence of Lymph Node Metastasis in Lower-third Gastric Cancer. Y. TAKASHIMA, S. KOMATSU, M. KASUGA, T. OHASHI, H. KONISHI, A. SHIOZAKI, T. KUBOTA, H. FUJIWARA, K. OKAMOTO, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	237
Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response. N. HARIMOTO, S. ITOH, T. YAMANAKA, K. HAGIWARA, N. ISHII, M. TSUKAGOSHI, A. WATANABE, K. ARAKI, T. YOSHIKUMI, K. SHIRABE ( <i>Maebashi; Fukuoka, Japan</i> ).....	245
Thyroid Hormones and Morphological Features of Primary Breast Cancer. A. MEIROVITZ, B. NISMAN, T.M. ALLWEIS, E. CARMON, L. KADOURI, B. MALY, O. MAIMON, T. PERETZ ( <i>Jerusalem, Israel</i> ) ....	253

Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer. M. AL-JUMAYLI, K. CHOUCAIR, A. AL-OBAYDI, R. PARK, A. BANSAL, J. BARANDA, W. SUN, A. SAEED ( <i>Kansas City; Wichita, KS; Tampa, FL; Kansas City, MO; Framingham, MA, USA</i> ) .....	59
Determinative Structural Features Identified With Probe-based Confocal Endomicroscopy for the Accurate Diagnosis of Gallbladder Malignancy. T. KOIZUMI, T. AOKI, T. YAMOCHI, Y. TASHIRO, T. YAMAZAKI, T. KUSANO, K. MATSUDA, Y. WADA, H. SHIBATA, K. SAITO, K. NOGAKI, T. HAKOZAKI, K. TOMIOKA, T. HIRAI, A. FUJIMORI, D.A. MANSOUR, A.E.A. GAHIN, R.M. HOFFMAN ( <i>Tokyo, Japan; Cairo, Egypt; San Diego, CA, USA</i> ) .....	67
Survival After Minimally Invasive Surgery in Older Women With Endometrial Carcinoma. J. CARDENAS-GOICOECHEA, Y. WANG, J.-H. LEE, M. SHORAKA, S.L. CARBAJAL-MAMANI, D. FISHMAN, A.N. RINER, J.G. TREVINO ( <i>Weston; Gainesville, FL; New York City, NY; Richmond, VA, USA</i> ) .....	75
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. M. LEHTONEN, J. SORMUNEN, M. HJÄLM-ERIKSSON, C. THELLENBERG-KARLSSON, T. HUTTUNEN, C. GINMAN, P.-L. KELLOKUMPU-LEHTINEN ( <i>Tampere; Helsinki; Turku, Finland; Stockholm; Umeå; Karlstad, Sweden</i> ) .....	87
Toxicities and Locoregional Control After External Beam Chest Wall and/or Regional Lymph Node Re-irradiation for Recurrent Breast Cancer. M. SAYAN, I. VERGALASOVA, I. JAN, S. KUMAR, N. CHAN, B.G. HAFFTY, N. OHRI ( <i>Boston, MA; New Brunswick, NJ, USA</i> ) .....	93
The Benefit of Postoperative Radiotherapy and Extending Neck Dissection in pT1-2 Oral Squamous Cell Carcinoma With a Single Ipsilateral Cervical Lymph Node Metastasis (pN1). U. ALSHARIF, D. STELLER, M. FALOUGY, L. THARUN, D. RADES, S.G. HAKIM ( <i>Lübeck; Dortmund; Witten, Germany</i> ) .....	97
Preoperative Risk Factors for Fibrosarcomatous Transformation in Dermatofibrosarcoma Protuberans. K.E. MALLETT, S. ALMUBARAK, R.M. CLAXTON, P.C. FERGUSON, A.M. GRIFFIN, P.S. ROSE, J.S. WUNDER, K. TSOI, M.T. HOUDEK ( <i>Rochester, MN, USA; Toronto, ON, Canada</i> ) .....	105
Prevalence of Diabetes and Impaired Fasting Glycemia in Patients With Oral Cancer: A Retrospective Study in Hungary. A. VEGH, D. BANYAI, M. UJPAL, K.S. SOMOGYI, Z. BICZO, G. KAMMERHOFER, Z. NEMETH, P. HERMANN, M. PAYER, D. VEGH ( <i>Budapest, Hungary; Graz, Austria</i> ) .....	109
Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer. S. HOSOYA, K. UEDA, S. ODAJIMA, K. OGAWA, H. KOMAZAKI, T. SEKI, M. TAKENAKA, M. SAITO, H. TANABE, K. YAMADA, H. TAKANO, Y. IIDA, N. YANAIHARA, A. OKAMOTO ( <i>Tokyo; Chiba, Japan</i> ) .....	115
Clinical Significance of Expression of Immuno-adjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer. Y. ASANO, S. KASHIWAGI, K. TAKADA, S. ISHIHARA, W. GOTO, T. MORISAKI, M. SHIBUTANI, H. TANAKA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ) .....	125
Clinical Impact of CYFRA 21-1 a Marker for Treatment Failure in Patients With Oropharyngeal Cancer Treated by Radio(chemo)therapy. S.A. RUDHART, P. LANGEN, K. THANGAVELU, F. GEHRT, P. STANKOVIC, T. WILHELM, B.A. STUCK, S. HOCH ( <i>Marburg; Borna, Germany</i> ) .....	137
Diagnostic and Prognostic Impact of Crypt Branching in Patients With Ulcerative Colitis: A Validation Study. C. LANG-SCHWARZ, C.A. RUBIO, M. VIETH ( <i>Bayreuth, Germany; Stockholm, Sweden</i> ) .....	147